No evidence of somatic FGFR3 mutation in various types of carcinoma

Mehdi Karoui, Hélène Hofmann-Radvanyi, Ute Zimmermann, Anne Couvelard, Claude Degott, Laetitia Faridoni-Laurens, Jean Charles Ahomadegbe, Sylvie Gazzeri, Elisabeth Brambilla, Thierry Clerici, Peggy Charbonnier, Christophe Tresallet, Emmanuel Mitry, Christophe Penna, Philippe Rougier, Catherine Boileau, Jean Paul Thiery, Bernard Nordlinger, Brigitte Franc, François Radvanyi

    Research output: Contribution to journalArticlepeer-review

    37 Citations (Scopus)

    Abstract

    Germline specific point mutations in the gene encoding fibroblast growth factor receptor 3 (FGFR3) are associated with autosomal dominant human skeletal dysplasia and craniosynostosis syndromes. Mutations identical to the germinal activating mutations found in severe skeletal dysplasias have been identified in certain types of cancer: at low frequency in multiple myeloma and cervix carcinoma and at high frequency in bladder carcinoma. We analysed, by SSCP and sequencing, the prevalence of FGFR3 mutations in 116 primary tumours of various types (upper aerodigestive tract, oesophagus, stomach, lung and skin). The regions analysed encompassed all FGFR3 point mutations previously described in severe skeletal dysplasia and cancers. No mutations were detected in the tumour types examined, suggesting that FGFR3 mutations are restricted to a few tumour types, the evidence to date suggesting that they are very specific to bladder carcinomas.

    Original languageEnglish
    Pages (from-to)5059-5061
    Number of pages3
    JournalOncogene
    Volume20
    Issue number36
    DOIs
    Publication statusPublished - 16 Aug 2001

    Keywords

    • Carcinoma
    • FGFR3
    • Growth factor receptor
    • Oncogene

    Cite this